Major Shareholder BVF Converts $20M Preferred Stock to Common, Boosting Stake to 43.3% Ahead of Merger

summarizeSummary

Major shareholder Biotechnology Value Fund converted $20.11 million in preferred stock to common shares at $4.03 each, increasing its stake to 43.3% of XOMA Royalty Corp ahead of its pending acquisition.

check_boxKey Events

• Strategic Preferred Stock Conversion

  Biotechnology Value Fund (BVF) and its affiliates converted 5,003,000 shares of Series X Preferred Stock into common stock at a conversion price of $4.03 per share, totaling $20.11 million.

• Significant Increase in Ownership

  This conversion boosts BVF's aggregate beneficial ownership to 7,593,303 common shares, representing 43.3% of XOMA Royalty Corp's outstanding stock.

• Pre-Merger Positioning

  The conversion occurred on May 14, 2026, shortly after the announcement of XOMA's acquisition by Ligand Pharmaceuticals for $39.00 per share, indicating a strategic move to consolidate voting power.

• Waiver of Notice Period

  The company waived a 61-day notice requirement, allowing BVF to increase its Series X Beneficial Ownership Limitation to 45% and proceed with the conversion rapidly.

auto_awesomeAnalysis

Biotechnology Value Fund (BVF) and its affiliates converted $20.11 million worth of Series X Preferred Stock into 5,003,000 common shares at a highly favorable price of $4.03 per share. This strategic move, occurring just before the company's acquisition by Ligand Pharmaceuticals for $39.00 per share, significantly increases BVF's beneficial ownership to 43.3% of XOMA's outstanding common stock. The conversion, which involved waiving a notice period, solidifies BVF's position and voting power, indicating strong conviction in the company's value or the merger's outcome.